After years of uncertainty, hospice M&A has reached a clear inflection point. Q4 2025 marked the strongest transaction volume since 2021, driven by premium platform deals that reset valuation benchmarks and restored buyer confidence. As interest rates ease and the valuation gap narrows, private equity is deploying capital more aggressively. According to Cory Mertz, buyers are backābut the bar for clinical integrity and compliance has never been higher.
